Entero Therapeutics Inc.
13F holders, Q1 2024 (March 31)6holders
$4.40avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding Entero Therapeutics Inc. in their 13F filings. The largest holders were Armistice Capital, LLC ($118K), Geode Capital Management, LLC ($48K) and Tower Research Capital LLC (TRC) ($10K).
- Company
- Entero Therapeutics Inc.
- Filed as
- FIRST WAVE BIOPHARMA INC (Q1 2024)
- CUSIP
- 33749P408
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $167K |
| Exits | 1 | $6K |
Ownership 6 holders
| Armistice Capital, LLC | 0.00% | New | 27,000 | $118K |
| Geode Capital Management, LLC | 0.00% | New | 10,847 | $48K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -15.6% | 2,393 | $10K |
| Wells Fargo & Company | 0.00% | Add +116.7% | 13 | $57 |
| US Bancorp \de | 0.00% | No change | 1 | $4 |
| Kathleen S. Wright Associates Inc. | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is ENTERO THERAPEUTICS INC's weight in each manager's 13F, not the share of Entero Therapeutics Inc. the manager owns.